Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leukemiachemotherapypatients mustpriorrelapsed
  Phrases that lowered it: japanesemalepartner20weeks before
• Sponsor's past termination rate: 21.3% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 35.4% (raises risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 23 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Collaborators: 1 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 684 (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 84.2% (lowers risk) · Drug's FDA history
• Allocation: not applicable (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy NCT02071901 · started 2014 · scored riskier than 83% of active trials completed
• A Safety and Efficacy Study of Eltrombopag in Subjects With AML NCT01890746 · started 2013 · scored riskier than 94% of active trials completed
• Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission NCT01656252 · started 2012 · scored riskier than 80% of active trials terminated
• Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS) NCT01893372 · started 2013 · scored riskier than 97% of active trials completed
• A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia NCT01440374 · started 2011 · scored riskier than 90% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.